---
title: "Aclaris Therapeutics (ACRS) Gets a Buy from Craig-Hallum"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285566579.md"
description: "Craig-Hallum analyst Adam Vogel has maintained a Buy rating on Aclaris Therapeutics (ACRS) with a price target of $10.00. Vogel, who focuses on the Healthcare sector, has an average return of 28.1% and a 93.75% success rate on his stock recommendations. Additionally, Piper Sandler also holds a Buy rating on Aclaris with a price target of $11.00."
datetime: "2026-05-07T13:55:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285566579.md)
  - [en](https://longbridge.com/en/news/285566579.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285566579.md)
---

# Aclaris Therapeutics (ACRS) Gets a Buy from Craig-Hallum

Craig-Hallum analyst Adam Vogel maintained a Buy rating on Aclaris Therapeutics today and set a price target of $10.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Vogel covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics, LB Pharmaceuticals, Inc., and Apogee Therapeutics. According to TipRanks, Vogel has an average return of 28.1% and a 93.75% success rate on recommended stocks.

In a report released on May 5, Piper Sandler also maintained a Buy rating on the stock with a $11.00 price target.

### Related Stocks

- [ACRS.US](https://longbridge.com/en/quote/ACRS.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LBRX.US](https://longbridge.com/en/quote/LBRX.US.md)
- [APGE.US](https://longbridge.com/en/quote/APGE.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)